

091847, 060.

C g C

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date listed below.

By:

Barbara Bryant
Barbara Bryant

Date:

January 25, 2005

PATENT

Attorney Docket No. P-090-US1

Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Number: U.S. 6,831,150 B2

Issued: December 14, 2004

Name of Patentee: Linsell

Title: REDUCTIVE ALKYLATION PROCESS

Certificate

FEB 08 2005

of Correction

**REQUEST FOR CERTIFICATE OF CORRECTION OF PATENT FOR
PTO MISTAKE (37 C.F.R. §1.322(a))**

ATTN: Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Assignee hereby requests that a certificate of correction be issued for the above-identified issued U.S. patent. The requested corrections are shown on the attached PTO/SB/44 form, which form is being submitted herewith in duplicate in a form suitable for printing.

I. CORRECTIONS REQUESTED FOR PTO MISTAKE PURSUANT TO 37 C.F.R. § 1.322(A)

The following mistakes in the issued U.S. patent are due to PTO error:

- (1) At column 29, line 28; and at column 33, line 34, please replace "-NR^cR^c, or -O-R^c;" with -- -NR^cR^c, or -O-R^c; --.

FEB 11 2005

This error is shown correctly, for example, on page 5, lines 3-4; and on page 10, text lines 2-3, respectively, of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

(2) At column 29, line 34, and at column 33, line 36, please replace " $-\text{CH}(\text{R}^c)-\text{NR}^c\text{R}^c$," with -- $-\text{CH}(\text{R}^c)-\text{NR}^c\text{R}^c$, --.

This error is shown correctly, for example, on page 5, lines 7-8, and on page 10, text line 5, respectively, of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

(3) At column 30, line 57, and at column 33, line 53, please replace " R^c is a saccharide group;" with -- R^c is a saccharide group; --.

This error is shown correctly, for example, on page 6, line 18 of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

(4) At column 31, line 3, and at column 33, line 62, please replace " $-\text{NR}^c\text{SO}_2\text{NR}^c-$," with -- $-\text{NR}^c\text{SO}_2\text{NR}^c-$, --.

This error is shown correctly, for example, on the second line from the bottom of page 6, and on page 11, line 10 respectively, of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

(5) At column 31, line 47, please replace " $-\text{CH}_2-\text{NR}^c\text{R}^c$ or $-\text{CH}_2-\text{NR}^a-$ " with -- $-\text{CH}_2-\text{NR}^c\text{R}^c$ or $-\text{CH}_2-\text{NH}-\text{R}^a-$ --.

This error is shown correctly, for example, on the bottom line of page 7 of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

(6) At column 32, bottom line, please replace "an aldehyde or ketone, a suitable base," with -- an aldehyde or ketone, a base, --.

This error is shown correctly, for example, on the bottom line of page 9 of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

(7) At column 33, line 37, please replace "-CH(R^c)-NR^cR^a-Y-R^b-(Z);" with --CH(R^c)-NR^c-R^a-Y-R^b-(Z); --.

This error is shown correctly, for example, on page 10, line 5, of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

(8) At column 33, line 57, please replace "OC(O)-," with --OC(O)-, --.

This error is shown correctly, for example, on page 11, line 7, of the "Amendment and Reply Pursuant to 37 C.F.R. § 1.111" submitted by Applicants on December 24, 2003.

Since the above errors are due to USPTO mistake, Assignee respectfully requests that a timely Certificate of Correction be issued to correct these mistakes.

II. FEE PAYMENT

Since this paper is being submitted to correct an error by the USPTO, no fee is believed to be required. However, if a fee is determined to be necessary, the Commissioner is hereby authorized to charge any fees required by this paper, and to charge any additional fees and credit any overpayment to Deposit Account No. 50-0344.

III. MAILING ADDRESS FOR CERTIFICATE

A certificate of correction issued for this U.S. patent should be sent to the following address:

Jeffrey A. Hagenah, Esq.
Theravance, Inc.
901 Gateway Boulevard
South San Francisco, CA 94080

IV. STATEMENT UNDER 37 C.F.R. § 3.73(B)


Theravance, Inc., a corporation, states that it is the assignee of the entire right, title and interest in the patent identified above by virtue of an Assignment from the inventor to Advanced Medicine, Inc. of U.S. Patent Application No. 09/847,060, recorded on July 20, 2001, at Reel 012001 and Frame 0660; and by virtue of a merger conveying the entire right, title and interest

from Advanced Medicine, Inc. to Theravance, Inc., recorded on June 14, 2002, at Reel 013003 and Frame 0075.

I, Jeffrey A. Hagenah, Assistant Secretary of Theravance, Inc., state that I am empowered to sign this statement on behalf of the assignee.

Respectfully submitted,
THERAVANCE, INC.

Date: January 24, 2005


Jeffrey A. Hagenah, Ph.D., Esq.
Reg. No. 35,175
(650) 808-6406

Correspondence Address:
THERAVANCE, INC.
Attn: Legal Dept.
901 Gateway Boulevard
South San Francisco, CA 94080
Tel: (650) 808-6000; Fax: (650) 808-6078

FEB 11 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO : 6,831,150 B2

DATED : December 14, 2004

INVENTOR(S): Martin S. LINSELL

It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:

Col. 29, line 28, replace "-NR^cR^c, or -O-R^c;" with -- -NR^cR^e, or -O-R^e; --; and
line 34, replace "-CH(R^c)-NR^cR^c;" with -- -CH(R^c)-NR^cR^e, --;

Col. 30, line 57, replace "R^c is a saccharide group;" with
-- R^e is a saccharide group; --;

Col. 31, line 3, replace "-NR^cSO₂NR^c-" with -- -NR^cSO₂NR^e-, --; and
line 47, replace "-CH₂-NR^cR^c or -CH₂-NR-R^a-" with
-- -CH₂-NR^cR^e or -CH₂-NH-R^a --.

Col 32, line 67, replace "un aldehyde or ketone, a suitable base," with
-- an aldehyde or ketone, a base, --.

Col. 33, line 34, replace "-NR^cR^c, or -O-R^c;" with -- -NR^cR^e, or -O-R^e; --;

line 36, replace "-CH(R^c)-NR^cR^c;" with -- -CH(R^c)-NR^cR^e, --;

line 37, please replace "-CH(R^c)-NR^cR^a-Y-R^b-(Z);" with
-- -CH(R^c)-NR^c-R^a-Y-R^b-(Z); --

line 53, replace "R^c is a saccharide group;" with
-- R^e is a saccharide group; --;

line 57, replace "OC(O)-," with -- -OC(O)-, --; and

line 62, replace "-NR^cSO₂NR^c-" with -- -NR^cSO₂NR^e-, --.

MAILING ADDRESS OF SENDER: Jeffrey A. Hagenah, Esq.
Theravance, Inc
901 Gateway Boulevard
South San Francisco, CA 94080

PATENT NO. 6,831,150 B2

No. of additional copies

 0

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

FEB 11 2005